144 related articles for article (PubMed ID: 9488603)
81. Phase II study of lonidamine in patients with metastatic breast cancer. An Eastern Cooperative Oncology Group study.
Robins HI; Neuberg DS; Benson AB; Pandya KJ; Tormey DC
Invest New Drugs; 1990 Nov; 8(4):397-9. PubMed ID: 2084074
[TBL] [Abstract][Full Text] [Related]
82. Activity of epirubicin and dibromodulcitol in advanced breast cancer. Results of the South-East European Oncology Group Study.
Eckhardt S; Juhos E; Hindy I; Jelic S; Koza I; László G; Mechl Z; Nagykálnay T; Pawlicki M; Schoket Z
Oncology; 1988; 45(6):409-12. PubMed ID: 3054671
[TBL] [Abstract][Full Text] [Related]
83. Pharmacokinetics and toxicity of oral and intravenous lonidamine in dogs.
Price GS; Page RL; Riviere JE; Cline JM; Thrall DE
Cancer Chemother Pharmacol; 1996; 38(2):129-35. PubMed ID: 8616902
[TBL] [Abstract][Full Text] [Related]
84. Experience with intermediate-dose (110-120 mg/m2) epirubicin.
Hickish T; Cunningham D; Haydock A; Coombes RC
Cancer Chemother Pharmacol; 1989; 24(1):61-4. PubMed ID: 2720892
[TBL] [Abstract][Full Text] [Related]
85. [Reducing the side effects of aggressive chemotherapy (cisplatin and epirubicin) with xenogenic peptides (factor AF2) in patients with hormone refractory metastatic prostate cancer. A prospective, randomized study].
Papadopoulos I; Wand H
Onkologie; 1989 Jun; 12 Suppl 3():26-31. PubMed ID: 2691943
[TBL] [Abstract][Full Text] [Related]
86. Efficacy of lonidamine combined with different DNA-damaging agents in the treatment of the MX-1 tumor xenograft.
Pratesi G; De Cesare M; Zunino F
Cancer Chemother Pharmacol; 1996; 38(2):123-8. PubMed ID: 8616901
[TBL] [Abstract][Full Text] [Related]
87. Lonidamine in metastatic breast cancer.
Rosso R; Amoroso D; Gardin G; Miglietta L; Guido T; Pace M; Repetto L; Pronzato P
Semin Oncol; 1991 Apr; 18(2 Suppl 4):62-5. PubMed ID: 2031200
[TBL] [Abstract][Full Text] [Related]
88. A rare case of large intracoronary thrombosis in advanced breast cancer patient treated with epirubicin and cisplatin.
Centola M; Lucreziotti S; Cazzaniga S; Salerno-Uriarte D; Sponzilli C; Carugo S
J Cardiovasc Med (Hagerstown); 2016 Dec; 17 Suppl 2():e241-e243. PubMed ID: 27606783
[TBL] [Abstract][Full Text] [Related]
89. A weekly schedule of epirubicin in pretreated advanced breast cancer.
Barni S; Archili C; Lissoni P; Paolorossi F; Crispino S; Tancini G
Tumori; 1993 Feb; 79(1):45-8. PubMed ID: 8497922
[TBL] [Abstract][Full Text] [Related]
90. Enhancement of cisplatin activity by lonidamine in human ovarian cancer cells.
Silvestrini R; Zaffaroni N; Villa R; Orlandi L; Costa A
Int J Cancer; 1992 Nov; 52(5):813-7. PubMed ID: 1428236
[TBL] [Abstract][Full Text] [Related]
91. Weekly epirubicin in advanced breast cancer.
Tucci E; Algeri R; Guarnieri A; Pepi F; Sapio L; Bastreghi G; Pirtoli L
Tumori; 1988 Dec; 74(6):689-92. PubMed ID: 3232214
[TBL] [Abstract][Full Text] [Related]
92. Toxicity and clinical tolerance of lonidamine.
Robustelli della Cuna G; Pedrazzoli P
Semin Oncol; 1991 Apr; 18(2 Suppl 4):18-22. PubMed ID: 2031192
[TBL] [Abstract][Full Text] [Related]
93. 4'epidoxorubicin plus verapamil in anthracycline--refractory cancer patients.
Demicheli R; Jirillo A; Bonciarelli G; Lonardi F; Balli M; Bandello A
Tumori; 1989 Jun; 75(3):245-7. PubMed ID: 2773076
[TBL] [Abstract][Full Text] [Related]
94. Cisplatin as first-line therapy for metastatic breast cancer.
Sledge GW; Loehrer PJ; Roth BJ; Einhorn LH
J Clin Oncol; 1988 Dec; 6(12):1811-4. PubMed ID: 3199166
[TBL] [Abstract][Full Text] [Related]
95. Lonidamine: efficacy and safety in clinical trials for the treatment of solid tumors.
Di Cosimo S; Ferretti G; Papaldo P; Carlini P; Fabi A; Cognetti F
Drugs Today (Barc); 2003 Mar; 39(3):157-74. PubMed ID: 12730701
[TBL] [Abstract][Full Text] [Related]
96. Phase II evaluation of Lonidamine in patients with advanced malignancy.
Evans WK; Shepherd FA; Mullis B
Oncology; 1984; 41 Suppl 1():69-77. PubMed ID: 6717899
[TBL] [Abstract][Full Text] [Related]
97. Phase II study of lonidamine in metastatic breast cancer.
Pronzato P; Amoroso D; Bertelli G; Conte PF; Cusimano MP; Ciottoli GB; Gulisano M; Lionetto R; Rosso R
Br J Cancer; 1989 Feb; 59(2):251-3. PubMed ID: 2930690
[TBL] [Abstract][Full Text] [Related]
98. Estimation of cardiotoxicity of epirubicin-cisplatin by determination of myoglobin.
Lechner W; Reider W; Hetzel H; Daxenbichler G; Marth C
Gynecol Obstet Invest; 1986; 22(1):42-6. PubMed ID: 3462098
[TBL] [Abstract][Full Text] [Related]
99. Symptomatic hypocalcemia and hypomagnesiemia in cisplatinum-based chemotherapy treated patients: case report.
Maina A; Richiardi G; Danese S; Defabiani E; Giardina G
Eur J Gynaecol Oncol; 1996; 17(4):281-2. PubMed ID: 8856305
[No Abstract] [Full Text] [Related]
100. Advanced breast cancer. A randomised trial of epidoxorubicin at two different dosages and two administration systems.
Ebbs SR; Saunders JA; Graham H; A'Hern RP; Bates T; Baum M
Acta Oncol; 1989; 28(6):887-92. PubMed ID: 2692652
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
